The short answer
Fish oil has not been shown to increase bleeding in a large cardiac-surgery trial, so blanket avoidance is not supported by that evidence. The trial did not report a heparin-specific result, leaving the exact combination less certain.
What this answer covers
Oral mixed EPA+DHA fish-oil products with injected unfractionated heparin; isolated high-dose EPA, other oils and different formulations require separate assessment.
- Supplement or preparation
- Fish Oil
- Medication ingredient
- heparin
A large trial measured actual bleeding
In 1,516 cardiac-surgery patients, prescription fish oil did not increase major perioperative bleeding versus placebo. The estimate was compatible with some uncertainty, and the fish-oil group received fewer transfused blood units. This is more informative than platelet tests alone.
Heparin applicability is indirect
The analysis found no significant difference in the treatment effect by preoperative antithrombotic therapy or bypass use. However, it did not isolate unfractionated heparin dose, route or co-use outcomes. It cannot provide a precise risk for an individual heparin regimen.
The formulation matters
The study used a prescription mixture of EPA and DHA in ethyl-ester capsules. A generic fish-oil label may describe a different concentration or preparation, and isolated EPA is not the same exposure. The study regimen is not a self-treatment recommendation.
No universal spacing or stopping rule
The evidence does not establish a protective dosing gap or a need for everyone receiving heparin to stop fish oil. Give the treatment or surgical team the exact product and amount so they can make an individual plan. Report bleeding promptly and do not alter heparin yourself.
Evidence and practical considerations
Side effects & toxicity
No heparin-specific clinical estimate and large indirect randomized bleeding trial was null; does not support a blanket increased-risk claim.
- Exact scope
- Oral mixed EPA+DHA fish-oil products with injected unfractionated heparin; isolated high-dose EPA, other oils and different formulations require separate assessment. with Unfractionated heparin sodium intravenous/subcutaneous, active-ingredient bridge to RxCUI5224 IN. Not LMWH or topical therapy.
- Medication form and route
- intravenous or subcutaneous unfractionated heparin; oral supplement
What remains uncertain
- No universal risk estimate, dose adjustment or spacing interval; source-specific limits apply.
Factors that may matter: Exact product; Dose/duration; Other antithrombotics; Bleeding risk; Kidney function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People receiving parenteral unfractionated heparin.
Heparin can cause hemorrhage; medicines inhibiting platelets can add bleeding concerns. Aldosterone suppression can cause hyperkalemia, especially with predisposing conditions or potassium-sparing medicines. Heparin is not absorbed through the gastrointestinal tract.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as heparin.
No botanical interaction specifically named. Not low-molecular-weight heparin, topical heparin cream or an oral anticoagulant; doses and risks of catheter flush products are not automatically equivalent.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 1,516 cardiac-surgery patients.
Major perioperative bleeding was not increased (OR0.81,95%CI0.53–1.24); fewer transfused units in fish-oil group. No significant effect modification by baseline antithrombotics or bypass use.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as heparin.
Secondary safety analysis; no heparin-specific exposure or treatment subgroup reported. Mixed EPA+DHA is not isolated EPA, and dose reflects fish-oil product rather than pure EPA+DHA mass.
Research assessment: · Open full citations ↗
Timing & monitoring
No universal avoidance or protective spacing interval; perioperative trial challenges routine fish-oil stopping but is not exact heparin proof.
- Exact scope
- Oral mixed EPA+DHA fish-oil products with injected unfractionated heparin; isolated high-dose EPA, other oils and different formulations require separate assessment. with Unfractionated heparin sodium intravenous/subcutaneous, active-ingredient bridge to RxCUI5224 IN. Not LMWH or topical therapy.
- Medication form and route
- intravenous or subcutaneous unfractionated heparin; oral supplement
What remains uncertain
- No universal risk estimate, dose adjustment or spacing interval; source-specific limits apply.
Factors that may matter: Exact product; Dose/duration; Other antithrombotics; Bleeding risk; Kidney function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People receiving parenteral unfractionated heparin.
Heparin can cause hemorrhage; medicines inhibiting platelets can add bleeding concerns. Aldosterone suppression can cause hyperkalemia, especially with predisposing conditions or potassium-sparing medicines. Heparin is not absorbed through the gastrointestinal tract.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as heparin.
No botanical interaction specifically named. Not low-molecular-weight heparin, topical heparin cream or an oral anticoagulant; doses and risks of catheter flush products are not automatically equivalent.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 1,516 cardiac-surgery patients.
Major perioperative bleeding was not increased (OR0.81,95%CI0.53–1.24); fewer transfused units in fish-oil group. No significant effect modification by baseline antithrombotics or bypass use.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as heparin.
Secondary safety analysis; no heparin-specific exposure or treatment subgroup reported. Mixed EPA+DHA is not isolated EPA, and dose reflects fish-oil product rather than pure EPA+DHA mass.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact-pair article preserving route, formulation, clinical-outcome and laboratory-endpoint distinctions. | |
| Research summary published |
Article revision: eb1cd435cd6b1dfe
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.